Hemp Stocks

584 Kommentare / 0 neu
03.01.2014 11:44
#1
Bild des Benutzers b00n
Offline
Kommentare: 5227
Hemp Stocks

 

 

Uruguay, Colorado Konsum legal

Div. US Bundesstaaten haben Medizinisches Marijane legalisiert...

weitere werden folgen..

nebst uruguay werden wohl noch andere Staaten in America sur folgen.

 

ganzer Sektor hat also enormes Wachstumpotential.

jetzt gilt es mal den spreu vom weizen zu trennen.

 

 

Ich fange mal an..

 


 

Aufklappen

----gesperrt wegen gutmenschentum, wünsche an der stelle allen alles gute, wie immer. http://investorshub.advfn.com/boards/profilea.aspx?user=193864

18.01.2017 08:40
Bild des Benutzers shanik82
Offline
Kommentare: 8
Lifestyle Delivery Systems mit disruptiven CannaStrips

Am Donnerstag habe ich in Frankfurt an einer Lunch-Präsentation mit Brad Eckenweiler, dem CEO der kanadischen Firma Lifestyle Delivery Systems (WKN: A14XHT), teilgenommen. Eckenweiler erklärte den rund 20 Teilnehmern das Geschäftsmodell der Gesellschaft und die Produkte.

Eckenweiler und das Team haben die sogenannten CannaStips entwickelt und patentiert. CannaStrips sind dünne Blättchen und enthalten Marihuana. Die CannaStrips sind auf der Zunge löslich und die über mehrere Stunden anhaltende Wirkung tritt laut Aussage des CEOs innerhalb kürzester Zeit ein.

Die CannaStrips werden in Kürze in vier verschiedenen Kategorien erhältlich sein. Je nach Anwendungsgebiet können die Konsumenten sich für ein schmerzlinderndes oder schlafförderndes Produkt für 1 USD erwerben. Die Marge liegt bei dem geschützten Produkt bei stolzen 87%. Der niedrige Preis hat das Potenzial zu einem disruptiven Albtraum für die Pharmabranche und dem illegalen Drogenhandel zu werden.

Spätestens im Januar 2017 sollen die CannaStrips in autorisierten Geschäften in Kalifornien, USA, frei erhältlich sein. Aus rechtlichen Gründen soll vorerst der Vertrieb auf den Sonnenstaat fokussiert sein. Wer vor 1980 geboren ist, kann sich wahrscheinlich noch daran erinnern, mit welcher Kreativität die Konsumenten zu Beginn der 90er Jahre die ersten Red Bull Dosen von Österreich nach Deutschland schmuggelten. Dass die Inhaltsstoffe von Red Bull damals hierzulande verboten waren, entwickelte sich zusammen mit aufkommenden Mythen zu einer staatlich-geförderten Marketingmaßnahme.

Das Unternehmen führt momentan eine Finanzierung in Höhe von 5 Mio. CAD zu 0,75 CAD pro Aktie durch. Die neuen Aktien werden zusammen mit einem halben Warrant mit einem Bezugsrecht einer neuen Aktie zu 1,50 CAD ausgegeben. Laut Eckenweiler ist die Finanzierung bereits mehrfach überzeichnet. Noch im Juni dieses Jahres wechselten die Aktien bei unter 0,10 CAD die Besitzer. Nur rund vier Monate später erreichten die Aktien im Oktober den Preis von 1,00 CAD. Am Freitag gingen die Aktien an der Heimatbörse in Kanada bei 0,69 CAD aus dem Handel.

Bei dieser plausibel und genial klingenden Geschäftsidee halte ich drei Szenarien für möglich: 1. Die CannaStrips werden ein Erfolg und das Unternehmen ist bald nicht mehr unter 40 Mio. CAD Wert, sondern geht in Richtung 1 Milliarde CAD Bewertung. 2. CannaStrips könnten ein Ladenhüter werden und in ein paar Jahren redet niemand mehr darüber oder 3., dass das Unternehmen so erfolgreich wird, dass es mit rechtlichem Gegenwind zu kämpfen hat. In diesem Zusammenhang spielt die neue Trump-Regierung auf Bundesebene eine wichtige Rolle. Wir werden sehen.

Quelle:http://www.derfinanzinvestor.de/Kommentare/Lifestyle-Delivery-Systems-mit-disruptiven-CannaStrips

17.01.2017 09:43
Bild des Benutzers Peter-Silie
Offline
Kommentare: 107

Auf www.reddit.com/r/weedstocks/ gäbe es ein weiteres Forum mit mehr Beiträgen (ist halt in Englisch). Dort werden auch ziemlich alle News sofort gepostet.

16.01.2017 22:28
Bild des Benutzers shanik82
Offline
Kommentare: 8
LDS News
16.01.2017 20:24
Bild des Benutzers Selector
Offline
Kommentare: 569

 

Info von CGC/Tweed  Smile Dirol

 

SMITHS FALLS, ON, Jan. 16, 2017 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: CGC) has closed the acquisition of the property at 1 Hershey Drive that currently houses Canopy Growth's headquarters and the Tweed Inc. (Tweed) production facilities.

"Increasing the scale of our cannabis production capacity is vitally important to our operations," said Bruce Linton, Chairman and CEO of Canopy Growth. "Even as a diversified producer using greenhouse growing and indoor growing facilities, we know there will be a need for commercial processing space that can be used to convert cannabis and cannabinoids into higher margin products like edibles, as well as complimentary products such as vape pens, or sophisticated medical delivery options that may be allowed under future legal frameworks. Almost tripling the footprint of our headquarters means more potential for our business, for the economy of Smiths Falls, and for Tweed's customers."

The entire 472,000 sq. ft. footprint could almost triple current production and processing capacity, making it by far the largest indoor cannabis production facility in Canada and likely the world. The 42-acre site could also house hundreds of thousands of square feet of additional production and processing space, either indoors or in greenhouse growing platforms.

Tweed has already transformed 168,000 sq. ft. of licensed space into Canada's most innovative cannabis production space. Twelve of 39 potential growing rooms are operational with another 12 multi-level growing rooms under construction and nearing completion. An R&D area has been used to drive innovation with some of Canada's leading researchers and universities. Oil extraction capabilities, a separate Dealer's Licence area, an in-house Quality Assurance lab, and the industry's only seed breeding area have all been added and brought online in the last three years.

The building, property and chattels were acquired for $6.6 million, of which $923,980 was settled with the issuance of 94,397 common shares of Canopy Growth, based on a 5-day VWAP of $9.7882 ending the day before closing.  The remainder was paid in cash on closing. As a part owner of the facility prior to the transaction, Bruce Linton received 70,800 of the 94,397 shares issued. These shares are subject to a 4-month lockup.

The acquisition is considered a "related party transaction" within the meaning of Multilateral Instrument 61-101 — Protection of Minority Security Holders in Special Transactions ("MI 61-101") because Bruce Linton, a director and officer of Canopy Growth is also a shareholder of the vendor Tweed Hershey Drive Inc. MI 61-101 provides that, unless exempted, an issuer proposing to undertake a related party transaction is required to prepare a formal valuation of the subject matter of the proposed transaction and to provide holders of the class of affected securities a summary of such valuation. MI 61-101 also requires that, unless exempted, the issuer seek approval of the transaction by a majority of the votes cast by the "minority" holders of the affected securities.

To ensure a fair valuation, John Bell, an independent Director of Canopy Growth led the purchase negotiation.  The Company also obtained an independent appraisal to support the final price negotiated.

Canopy Growth has relied on an exemption available pursuant to MI 61-101 from the formal valuation and minority approval requirements. MI 61-101 provides that if, at the time the transaction is agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for the transaction, insofar as it involves interested parties, exceeds 25% of the issuer's market capitalization (calculated in accordance with MI 61-101), the formal valuation and minority approval requirements do not apply to such transaction. The acquisition of 1 Hershey Drive is exempt from the formal valuation and minority approval requirements of MI 61-101 because neither the fair market value of 1 Hershey Drive nor the fair market value of the purchase price for the acquisition of 1 Hershey Drive exceeds 25% of Canopy Growth's market capitalization.

The consideration paid was provided for in the Use of Proceeds in a recently completed bought deal, which closed on December 22, 2016.  The Smiths Falls facility and significant improvements completed, underway and planned will act as an important asset and security that could be viewed favourably by commercial institutional lenders to recycle the equity invested and finance future expansion plans with non-dilutive funding at competitive rates. The Company previously leased Tweed's production and office space at 1 Hershey Drive, an arrangement that permitted the Company to defer the financial burden of unused portions of the building, which have sat vacant since 2008 when Hershey Canada Inc. vacated the property, until the commercial opportunity supported the need to expand the Company's operating footprint.

"The future looks bright for Tweed and Canopy Growth's operations in this facility," continued Linton. "It might even be time to reopen the famous Visitor Centre and start training tour guides."

Here's to Future Growth.

About Tweed
Tweed is a globally recognized marijuana production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn't just sell marijuana, it facilitates a conversation about a product we've all heard about but haven't met intimately yet. It is approachable and friendly, yet reliable and trusted. As marijuana laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly‑owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity. Canopy Growth has established partnerships with leading sector names in Canada and abroad. For more information visit www.canopygrowth.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Canopy Growth Corporation
 

For further information: Jordan Sinclair, Director of Communications, Jordan@tweed.com, 613-769-4196; Investor Relations, Tyler Burns, Tyler.burns@canopygrowth.com, 855-558-9333 ex 122; Director: Bruce Linton, tmx@tweed.com

RELATED LINKS
http://canopygrowth.com/

http://www.newswire.ca/news-releases/canopy-growth-triples-tweeds-produc...

09.01.2017 12:25
Bild des Benutzers petra129
Offline
Kommentare: 33

CAN MJ CGC MT APH ACB OGI Technical Analysis Chart 1/6/2017 by ChartGuys.com

 

https://www.youtube.com/watch?v=cCwojF_l40w&t=22s&hd=1

09.01.2017 12:04
Bild des Benutzers petra129
Offline
Kommentare: 33

@Peter... ja habe mir auch wieder ein paar geposchtet - allerdings teurer als mein vorheriger Abgang Sad

hier noch zwei kurze Videos über Marijuana:

https://www.youtube.com/watch?v=n2KozLOjxXE&hd=1

https://www.youtube.com/watch?v=ENRa3-R6Ogw&hd=1

06.01.2017 10:54
Bild des Benutzers Peter-Silie
Offline
Kommentare: 107

Hab mir mal noch eine Portion APH.TO ins Depot gelegt Smile sollte die Fusion von CGC und MT zustandekommen, wären sie dann die 2 grössten Produzenten in Kanada, positiv ist auch, dass sie bereits Gewinn schreiben.

05.01.2017 21:37
Bild des Benutzers shanik82
Offline
Kommentare: 8
LDS - Canna Strips
03.01.2017 22:55
Bild des Benutzers Selector
Offline
Kommentare: 569

Danke für die Info. Hier noch von heute CGC's Jahresrückblick:

Wink

 

Canopy comments on cannabis product recalls in 2016

 

2017-01-03 13:29 ET - News Release

 

Mr. Bruce Linton reports

CANOPY GROWTH CORPORATION COMMENTS ON THE YEAR THAT WAS 2016

Canopy Growth Corp. is offering the following commentary on the events of late 2016.

Transitioning Canadians into the legal cannabis system with the appropriate checks and balances has been very successful to date. The number of authorized medical cannabis users tripled in 2016 as health care professionals and individuals became increasingly aware of the emerging regulated system, and as the system itself evolved to better meet Canadians' needs.

Since May, 2014, when Tweed shipped its first gram, its facilities have evolved and become more efficient. Each stage of production and processing has dozens of standard operating procedures that make its products better and safer. Through hard work and a culture of improving every aspect of the company's operations as it grows, Canopy Growth has earned almost a quarter of the market share and developed a strong record of compliance across multiple facilities.

Canada is ahead of the global curve with regards to cannabis regulation. The system in place today has successfully introduced over 100,000 Canadians to a legal source of cannabis for medical purposes. The success of the access to cannabis for medical purposes regulations is evident in its growth, which has continued at a rate of approximately 10 per cent per month for more than two straight years. Quality of product is improving across the sector, while average prices have come down. Patients now have cannabis oils and capsules to choose from, in addition to a variety of dried cannabis options.

Late last year, the company's sector was met with two announced product recalls and some related negative media coverage. These instances were of course unfortunate. As neither recall was related to Canopy Growth or its subsidiaries, Canopy is in no position to comment on the details related to the product recalls. One of the companies, however, is set to join the Canopy family, and the company remains proud of the reputation Mettrum has built for its quality products, customer support and physician outreach.

It is important to note that recalls are not the sign of a system in disarray; rather, they are signs that the system is working to protect Canadian patients. This is true of all regulated industries, from food production to medical production, but it is especially important in a sector such as the cannabis industry, which remains in its infancy and subject to incredible scrutiny.

All licensed producers are highly regulated, tracking every plant from seed to sale, testing product for release and maintaining samples in case further testing is required. Additionally, and unique to the company's sector given the direct relationship it has with its patients, every licensed producer has procedures in place to contact every one of its clients if a recall or other customer notification needs to occur. Upon discovering anything warranting a recall, such as the presence of unapproved treatment products, a licensed producer will ensure that impacted customers are identified, and advised of the recall and of any potential risks associated with product consumption. Furthermore, substantial testing and reviews of procedures will occur to ensure that corrective actions are put in place and implemented.

In the case of Mettrum's disclosed recall, it was concluded by Health Canada and external experts that the recall constituted a Type 3 recall, defined by Health Canada as a situation in which the use of, or exposure to, a product is not likely to cause any adverse health consequences. All patients who are potentially impacted are notified, corrective actions are put in place, and existing product and procedures retested and examined.

Looking to the future, there are no signs of things slowing down for the company's sector or the company. In spite of the fact that illegal sources exist, Canadians requiring cannabis for medical purposes increasingly place their trust in a system that delivers high-quality products, and has safeguards in place to recognize and react in the rare cases when that standard is not met. The company is not perfect, nor is the system in which it operates. There will be bumps along the road, but, for a new sector, there is a lot to take pride in.

As the company enters a new year that will undoubtedly see the topic of cannabis debated everywhere from the water cooler to the floor of the House of Commons, it is important that the successes of the current system are recognized, its shortcomings are identified and addressed, and a uniquely Canadian cannabis sector is created that can continue to improve the lives Canadians, and ensure a safe, reliable and regulated supply of cannabis products.

About Canopy Growth

Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms. Through its wholly owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over 500,000 square feet of indoor and greenhouse production capacity.

We seek Safe Harbor.

© 2017 Canjex Publishing Ltd. All rights reserved.

03.01.2017 09:25
Bild des Benutzers petra129
Offline
Kommentare: 33

http://finance.yahoo.com/video/oddball-marijuana-laws-books-234921110.html

....keine spezifischen Aktien - aber von allgemeinem Interesse denke ich.

23.12.2016 18:54
Bild des Benutzers Emil
Offline
Kommentare: 2865

Also dies finde ich mega cool:

Heute,

https://www.tweed.com/blogs/blog

@ REMI,

 

Emil

21.12.2016 23:35
Bild des Benutzers Selector
Offline
Kommentare: 569

Und dann noch dies:

 

Canopy Growth unit closes $7-million financing

 

2016-12-21 14:58 ET - News Release

 

Mr. Bruce Linton reports

CANOPY HEALTH INNOVATIONS CLOSES FINANCING & ANNOUNCES LEADERSHIP APPOINTMENT

Canopy Growth Corp.'s recently formed Canopy Health Innovations (CHI) has closed an offering to sell common shares in CHI for gross proceeds of approximately $7-million. CHI will use the proceeds to establish general operations and begin clinical research (in partnership with licensed third parties, including Canopy Growth) into the effectiveness of clinically ready whole-plant cannabis drug formulations and dose delivery systems on specific indications.

CHI will operate as a pure research incubator and is strategically positioned and focused on creating an IP portfolio that can be built into commercial opportunities for Canopy Growth and its subsidiaries.

Pursuant to agreements entered into between CHI and Canopy Growth, Canopy Growth and its subsidiaries will work closely with CHI, whereby Canopy Growth will act as a primary supplier of cannabis products for clinical research; as a research partner through its subsidiary Tweed Inc., which recently acquired a controlled drugs and substance dealer's licence from Health Canada, allowing it to, among other things, possess cannabis and cannabis byproducts for the purposes of analytical testing; and in the commercialization of IP created by CHI.

"Canada is in a unique leadership position with respect to cannabis research and cannabis IP," said Bruce Linton, chairman of CHI and chairman and chief executive officer of Canopy Growth. "Our intention with CHI is to build an extension of the business that is dedicated to product specialization. By defining, in clinical terms, how to apply specific cannabis profiles and delivery systems to certain conditions, we can drive physician acceptance and grow the market at the same time."

Also, Marc Wayne will join CHI as founding president and director. Mr. Wayne is well regarded as a pioneer in the Canadian medical cannabis field, having both co-founded Bedrocan Canada, one of Canada's first licensed producers, and the Cannabis Canada Association (formally CMCIA), acting as its founding chair. Mr. Wayne was also instrumental in helping to develop the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and turning it into a global innovator in education and research on the medical uses of cannabis. With his years of start-up and executive management experience, Mr. Wayne is ideally suited to lead this health- and research-focused enterprise during this critical time for cannabis research.

"This is a very exciting time for cannabis research and the possibility to take whole-plant cannabis therapies to another level," said Mr. Wayne. "Canada is well positioned with its current regulatory environment to lead in this area. The calls for more research into cannabis have been heard, and I am honoured to have the opportunity to lead CHI as a credible first mover into this area."

Effective upon the closing of the offering, Mr. Wayne has resigned his position as managing director of Canopy Growth and as president of Bedrocan Canada Inc. in order to focus his attention on CHI. The Canopy Growth management team and board of directors wish to deeply thank Mr. Wayne for his instrumental role in forming Canopy Growth and his dedication to medical cannabis work, which will continue and accelerate at CHI.

CHI is currently owned in part by Canopy Growth and private investors. The corporate vision of CHI is to increase the understanding of cannabis-based therapies through research, drive product innovation and build intellectual property in the medical cannabis industry.

We seek Safe Harbor.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2432341

 

 

 

 

21.12.2016 13:46
Bild des Benutzers Selector
Offline
Kommentare: 569

Hier aber kann man was lesen betr. CGC:  Wink

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:CGC-2432094

 

Canopy Growth to list 5,662,000 more shares on TSX

 

2016-12-20 18:24 ET - Prospectus Approved

 

Canopy Growth Corp. will list an additional 5,662,000 shares at the open on Dec. 22, 2016, according to the Toronto Stock Exchange. As stated in the company's Dec. 16, 2016, short form prospectus, Canopy Growth will issue 5,662,000 shares at $10.60 per share. It has granted to the underwriters an overallotment option to buy 849,300 more shares at the same price for 30 days following the closing of the offering.

© 2016 Canjex Publishing Ltd. All rights reserved.

 

 

 

 

20.12.2016 09:57
Bild des Benutzers Peter-Silie
Offline
Kommentare: 107

petra129 hat am 16.12.2016 - 19:05 folgendes geschrieben:

@Peter-Silie - ich versteh das auch nicht. Im Mettrum Forum liest man nichts, im Canopy-Forum findet man etwas, aber den wirklichen Durchblick haben die wohl auch (noch) nicht.

http://www.stockhouse.com/companies/bullboard/v.cgc/capital-gold-corpora...

vielleicht findest Du bei Canopy etwas in nächster Zeit?!?!

 

Die Fusion muss ja noch genehmigt werden im Januar..Sonst sehe ich eigentlich keine anderen Gründe. 

 

19.12.2016 16:17
Bild des Benutzers petra129
Offline
Kommentare: 33

CAN MJ CGC MT APH ACB SPRWF OGI Technical Analysis Chart 12 /16/2016 by ChartGuys.com

 

https://www.youtube.com/watch?v=8IZg83hYVCI

Video mit Charts ab 1:43

16.12.2016 19:05
Bild des Benutzers petra129
Offline
Kommentare: 33

@Peter-Silie - ich versteh das auch nicht. Im Mettrum Forum liest man nichts, im Canopy-Forum findet man etwas, aber den wirklichen Durchblick haben die wohl auch (noch) nicht.

http://www.stockhouse.com/companies/bullboard/v.cgc/capital-gold-corpora...

vielleicht findest Du bei Canopy etwas in nächster Zeit?!?!

16.12.2016 15:53
Bild des Benutzers Peter-Silie
Offline
Kommentare: 107
MT / CGC Merger

Hallo zusammen Smile

 

Der Merger von Canopy und Mettrum steht ja kurz bevor, kann jemand erklären, warum eine so grosse Differenz zum Wandlungspreis besteht? Pro Mettrum Aktie bekommt man ja ca. 0.71 CGC.. Der Kurs von Mettrum steht aber einiges tiefer? Ist eine zu grosse Unsicherheit vorhanden, dass der Zusammenschluss nicht durchgeführt wird?

 

Grüsse Peter-Silie

14.12.2016 16:03
Bild des Benutzers logn
Offline
Kommentare: 330

Selector hat am 06.12.2016 - 12:53 folgendes geschrieben:

Danke euch für die Infos.

@logn

betr. Marapharm sind diese nicht zum Onlinetrading freigegeben (OTC) ?  und falls die zum Pennystock werden könnten,

fliegen sie in USA raus. Lasse ich.

Info bei Cash: Dieser Titel ist nicht zum Handel im e-banking freigeschaltet. Für telefonischen Handel oder Auskunft wählen Sie bitte 00800 0800 55 55.

Listing: CNQ, FRA, STU, OTN, NQB und FSE (Quelle: Telekurs).

 

Marapharm Ventures Inc. beginnt mit den Bauarbeiten auf seinem Grundstück in Las Vegas (Nevada)

Kelowna, British Columbia, Kanada - 7. Dezember 2016, Marapharm-Symbole: Kanada - CSE:MDM / Deutschland - FWB:2M0 / Vereinigte Staaten - OTCQB:MRPHF

Marapharm Ventures Inc. (Marapharm) gibt bekannt, dass die Bauarbeiten auf seinem 7 Acres grossen Grundstück im Apex Industrial Park in Las Vegas (Nevada) nun im Gange sind. Am 14. November 2016 wurde bekannt gegeben, dass zwei erste Gebäude mit einer Fläche von 5.000 Quadratfuss bei CECO Building Systems beauftrag wurden. Der Auftrag ist nun fertiggestellt, die Gebäude wurden gefertigt und werden nach Plan am 19. Dezember 2016 angeliefert werden. Die ersten Platzbauarbeiten wurden abgeschlossen und der Gebäudestandort wird von Patriot Grading für die Schalungen und die Plattengründung vorbereitet. Eine 12 mal 20 Fuss grosse Reklametafel mit dem Logo des Unternehmens und dem Slogan Watch us grow wird vor Ort aufgestellt werden. Der Bebauungsplan und die Genehmigungen für das erwartete Staubaufkommen liegen vor. Eine temporäre Umzäunung wurde errichtet. Mit Master Association wurde eine Vereinbarung hinsichtlich der Schuttreste, die für den Bau notwendig sind, getroffen und das Material wird Marapharm kostenlos zur Verfügung gestellt.

Las Vegas verzeichnet jedes Jahr mehr als 50 Millionen erwachsene Besucher. Marihuana wurde in Nevada nun auch als Genussmittel legalisiert. Und wir erreichen die von uns gesteckten Ziele, sagte Linda Sampson, CEO von Marapharm.

ÜBER MARAPHARM VENTURES INC.

www.marapharm.com

Marapharm ist im Besitz von 300.000 Quadratfuss umfassenden lizensierten Flächen und Anlagen für den Anbau und Verkauf von medizinischem Marihuana in den US-Bundesstaaten Washington und Nevada. In Kanada beantragte Marapharm vor zweieinhalb Jahren eine Produktions- und Verkaufslizenz gemäss den MMPR-Richtlinien und hat die Unbedenklichkeitsbescheinigungen erhalten. Der Antrag wird derzeit dem eingehenden Prüfverfahren unterzogen. Im September 2016 wurde Marapharm von Health Canada kontaktiert und darüber informiert, dass es für Marapharm zulässig ist, den derzeit von Health Canada geprüften Antrag zu ergänzen und die vor kurzem eingeführten ACMPR-Bestimmungen einzubinden.

Weitere Informationen zu den Betriebs- oder Finanzergebnissen von Marapharm entnehmen Sie bitte den bei den zuständigen Wertpapieraufsichtsbehörden vorliegenden Berichten, die über die CSE-Website (www.thecse.com), die OTC-Website (www.otcmarkets.com) und die SEDAR-Website (www.sedar.com) unter dem Unternehmensprofil von Marapharm Ventures Inc. eingesehen werden können.

 

14.12.2016 08:13
Bild des Benutzers Selector
Offline
Kommentare: 569

Erfreuliches von CGC:

SMITHS FALLS, ON, Dec. 13, 2016 /CNW/ - After a preliminary review of the findings of the special Task Force which today released recommendations on the regulation of recreational cannabis, Bruce Linton, Chairman and CEO of Canopy Growth Corporation (TSX: CGC) wishes to issue the following statement: 

"This report is good news for Canadians and in our view provides a strong policy framework for the government to consider. Most importantly, we think it confirms that the current medical system for production is working and should form the backbone of ongoing production into the future. It recognizes the value of limited grow-at-home and diversity of producers and access methods, all things we support as a Company. It also recognizes that the existing mail order system has merit as an ongoing complementary distribution system reaching all Canadians conveniently and securely." 

"We have concerns that the Task Force is recommending no differentiated tax regime for medical and recreational sales, which has the potential to unduly burden cannabis patients. A path forward to insurance coverage must also remain a top priority for Canadian policymakers. Cannabis access can only truly be achieved if barriers to affordability are removed."

"On branding, we certainly agree with the need to limit promotion of cannabis, particularly anything that promotes the product to children or encourages irresponsible consumption. In our view, however, cannabis is not the same as tobacco or alcohol and merits its own carefully considered framework. Packaging debates are driven by public health concerns and rules surrounding packaging and promotion need to be balanced against cannabis's unique existence in the black market and the relative harms it presents to society and youth." 

"Lastly, on the topic of 'corporate cannabis', we are proud of the hundreds of jobs we have created, the millions of dollars we have spent in Canadian communities building world-class production facilities, the thousands of doctors and researchers we have visited, the tens of thousands of patients we serve, and that we are building an innovative global cannabis company based right here in Canada. Our investments result in improved support, variety and quality for Canadian customers and we are proud to always seek to advance the dialogue on cannabis policy. We are privileged to be a part of this exciting change, and look forward to expanding on our contributions in this sector over the months and years to come." 

"Many details still need to be worked through but this appears to be a very promising start to a successful Canadian policy framework, and we are thankful to the Task Force for their hard work in bringing concise policy recommendations forward on a very complex issue."

 

SOURCE Canopy Growth Corporation
 

For further information: Jordan Sinclair, Director of Communications, Jordan@tweed.com, 613-769-4196; Investor Relations: Tyler Burns, Tyler.burns@canopygrowth.com, 855-558-9333 ex 122; Director: Bruce Linton, txm@tweed.com

RELATED LINKS
http://canopygrowth.com/

 

 

08.12.2016 16:44
Bild des Benutzers Emil
Offline
Kommentare: 2865

Emil

06.12.2016 12:53
Bild des Benutzers Selector
Offline
Kommentare: 569

Danke euch für die Infos.

@logn

betr. Marapharm sind diese nicht zum Onlinetrading freigegeben (OTC) ?  und falls die zum Pennystock werden könnten,

fliegen sie in USA raus. Lasse ich.

Info bei Cash: Dieser Titel ist nicht zum Handel im e-banking freigeschaltet. Für telefonischen Handel oder Auskunft wählen Sie bitte 00800 0800 55 55.

05.12.2016 21:08
Bild des Benutzers petra129
Offline
Kommentare: 33

4 Canadian Marijuana Stocks That Could Be Acquired Soon

posted December 05, 2016 02:49 pm  by  sunny3999

     With signs of industry consolidation, the Canadian marijuana stocks on our list might get gobbled up in good time SmallCapPower | December 5, 2016: As Canopy Growth...read more With signs of industry consolidation, the Canadian marijuana stocks on our list might get gobbled up in good time

SmallCapPower | December 5, 2016: As Canopy Growth Corporation (TSE:CGC) announced recently that it has agreed to acquire Mettrum Health Corp. (CVE:MT), the Number 5 producer by market cap, it leaves a lot for other producers to consider. If the transaction is completed, Canopy will effectively control half of the registered patients under Health Canadians ACMPR. With Aurora Cannabis Inc. (CVE:ACB), and Aphria (CVE:APH) being the Number 2 and Number 3 producers, respectively, they must be thinking about what they are going to do to expand their market share. Although unlikely, it is possible that they merge together to rival the size of the new Canopy Growth Corp., but they could also be eyeing the smaller players in the space. The Canadian marijuana stocks on our list today could be the next ones up for consolidation as the major players look to establish a strong dominance ahead of legalization.

OrganiGram Holdings Inc. (CVE:OGI) – $3.27
Pharmaceuticals Marapharm Ventures Inc. (CSE:MDM) – $1.78
Pharmaceuticals
  Supreme Pharmaceuticals Inc. (CSE:SL) – $1.78
Pharmaceuticals
 ICC International Cannabis Corp. (CVE:ICC)- $1.57
Pharmaceuticals ausführlich:
4 Canadian Marijuana Stocks That Could Be Acquired Soon

 

  

05.12.2016 17:53
Bild des Benutzers petra129
Offline
Kommentare: 33
b00n

....was ist aus b00n geworden? Habe zurück geblättert und ihn das letzte mal vor knapp einem Jahr gefunden. In Uruguay? Wünsche ihm jedenfalls nur das Beste - hat er doch diese Geschichte gestartet Give rose

05.12.2016 13:39
Bild des Benutzers petra129
Offline
Kommentare: 33

logn hat am 02.12.2016 - 19:43 folgendes geschrieben:

Selector hat am 01.12.2016 - 20:42 folgendes geschrieben:

https://www.tweed.com/blogs/blog

Ja, man kann sie noch schön anwachsen lassen, sicher bis zur dieser Sitzung im Januar dann mal. Ev. werde ich dann nachfassen, ev. auch zu 11.80, falls nötig.

Auch von heute:

http://www.profitconfidential.com/stock/canopy-growth-430-million-deal-huge-pot-stocks/

 

@ Selector

Bis Ende Q1 2017 könnte Marapharm spannend werden.... Glaube das Unternehmen wurde bislang noch nicht erwähnt - deshalb melde ich mich auch wieder mal zu Worte.

Wünsche ein angenehmes Wochenende.

 

 

....immer interessant:

 

 

02.12.2016 19:43
Bild des Benutzers logn
Offline
Kommentare: 330

Selector hat am 01.12.2016 - 20:42 folgendes geschrieben:

https://www.tweed.com/blogs/blog

Ja, man kann sie noch schön anwachsen lassen, sicher bis zur dieser Sitzung im Januar dann mal. Ev. werde ich dann nachfassen, ev. auch zu 11.80, falls nötig.

Auch von heute:

http://www.profitconfidential.com/stock/canopy-growth-430-million-deal-huge-pot-stocks/

 

@ Selector

Bis Ende Q1 2017 könnte Marapharm spannend werden.... Glaube das Unternehmen wurde bislang noch nicht erwähnt - deshalb melde ich mich auch wieder mal zu Worte.

Wünsche ein angenehmes Wochenende.

 

 

01.12.2016 20:42
Bild des Benutzers Selector
Offline
Kommentare: 569

https://www.tweed.com/blogs/blog

Ja, man kann sie noch schön anwachsen lassen, sicher bis zur dieser Sitzung im Januar dann mal. Ev. werde ich dann nachfassen, ev. auch zu 11.80, falls nötig.

Auch von heute: Biggrin

http://www.profitconfidential.com/stock/canopy-growth-430-million-deal-huge-pot-stocks/

 

01.12.2016 15:51
Bild des Benutzers Emil
Offline
Kommentare: 2865

Mega super, dass ich was habe, das auch im Winter wächst. Ich meine natürlich CGC. Yes 3

Emil

01.12.2016 09:36
Bild des Benutzers Selector
Offline
Kommentare: 569

CGC wächst und wächst... SmileDirol

Schöner Deal:

 

http://www.newswire.ca/news-releases/canopy-growth-enters-into-agreement-to-acquire-mettrum-603929436.html

Canopy Growth enters into agreement to acquire Mettrum

ignificant additional production capacity and brand diversification to Canopy Growth, Canada's leading cannabis company

  • Canopy Growth will add two national brands to its portfolio, increasing its production platform to 665,000 sq. ft., and furthering its position as a domestic and global leader.
  • Acquisition provides Canopy Growth with a full-spectrum product offering including expansion of medically-focused & lifestyle brands and the addition of a natural hemp brand.
  • Acquisition rounds out best in class management with significant industry experience.
  • Acquisition allows for sharing of best practices and production standards, with the potential to reduce costs and realize revenue synergies.
  • Mettrum shareholders to receive 0.7132 common shares (the "Exchange Ratio") of Canopy Growth for each common share of Mettrum.

SMITHS FALLS, ON and TORONTO, Dec. 1, 2016 /CNW/ - Canopy Growth Corporation (TSX: CGC) ("Canopy Growth" or the "Company") and Mettrum Health Corp. ("Mettrum") (TSXV: MT) are pleased to announce that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which Canopy Growth will acquire all of the issued and outstanding shares of Mettrum (the "Arrangement"), creating a world-leading diversified cannabis company with six licensed facilities, and a licensed production footprint of approximately 665,000 sq. ft., with significant acreage for expansion.

The total transaction is valued at approximately C$430 million and will be satisfied by the issuance of common shares in Canopy Growth. Under the terms of the Arrangement Agreement, Mettrum shareholders will be entitled to receive 0.7132 common shares of Canopy Growth for each common share of Mettrum, representing consideration of C$8.42 per Mettrum common share based on the closing price of Canopy Growth common shares on the Toronto Stock Exchange ("TSX") on November 30, 2016.  Upon completion of the Arrangement, existing Canopy Growth and Mettrum shareholders are expected to own approximately 77.7% and 22.3%, respectively, of the pro forma company.

Strategic Rationale

  • Dominant Market Position: Post-acquisition, Canopy Growth will continue to fortify its position as the largest medical marijuana company in Canada and as a global leader with total licensed production square footage of approximately 665,000 sq. ft., with significant acreage for additional expansion.
  • Expanded and Diversified Portfolio of Nationally Recognized Cannabis and Hemp Brands: The combined company will bring together Mettrum's simple, recognizable and proven Mettrum Spectrum brand, with the pure medically-focused brand of Bedrocan Canada and the approachable, lifestyle-focused brand of Tweed. On the hemp side of the business, the integration of Mettrum Originals with Canopy Growth's recently acquired hemp.ca platform will solidify Canopy Growth's position in the hemp market.
  • Cost and Revenue Synergies: The Company expects to realize improved supply chain management and back office efficiencies, cross-selling to customers given broader product offerings and combined research capabilities.
  • Industry-Leading Management Team: The combined company will have best in class management with significant and diverse industry experience.
  • Well-Capitalized for Further Global Growth: Post acquisition, Canopy Growth's cash balance of approximately $68 million positions the Company with one of the strongest balance sheets in the industry and leaves the Company well-funded for expansion and product development initiatives.
  • Enhanced Financial Scale and Presence: A widely-recognized and scalable platform to attract additional patients and to position the Company favourably within all distribution channels.

"From day one, Canopy Growth has viewed production capacity, brand diversity, and highly-skilled management as the foundational aspects of our business," said Bruce Linton, Chairman and CEO of Canopy Growth.  "Mettrum has established a line of cannabis products that work well in a medical context and will transition naturally into a natural and healthy lifestyle market. Their substantial production facilities will add to our growing production platform as we expand to meet the needs of patients, and their experienced personnel will help Canopy Growth drive our vision forward to the next level." Added Linton: "Both Canopy Growth and Mettrum have proven themselves with Canadian patients; and together we intend to make our industry-leading product and service offering even stronger, while developing our common hemp objectives."

"Canopy Growth and Mettrum have enjoyed a collaborative industry relationship working on a number of patient and industry advocacy efforts," said Michael Haines, CEO of Mettrum. "Combining our companies' complimentary market strengths, and management expertise, should result in a more dynamic company well-positioned for emerging recreational and international opportunities."

Arrangement Summary

The Arrangement Agreement provides that Mettrum shareholders will be entitled to receive 0.7132 common shares of Canopy Growth for each common share of Mettrum held, representing consideration of C$8.42 per Mettrum common share based on the closing price of Canopy Growth common shares on November 30, 2016. Upon closing of the acquisition, Mettrum will become a wholly-owned subsidiary of Canopy Growth.

Each of the executive officers and directors of Mettrum, who together hold approximately 15% of the outstanding common shares of Mettrum have entered into voting support agreements in favour of the Arrangement.

The Arrangement Agreement provides that Mettrum is subject to non-solicitation provisions and provides that the Special Committee of Mettrum may, under certain circumstances, terminate the Arrangement in favour of an unsolicited superior proposal, subject to a termination fee of C$10 million (the "Termination Fee") to Canopy Growth and subject to a right to match the superior proposal. The Arrangement Agreement includes other customary termination provisions where a Termination Fee is payable to Canopy Growth or Mettrum under certain circumstances.

The acquisition will be carried out by way of plan of arrangement under the Business Corporations Act (Ontario) and will require the approval of at least 66 2/3% of the votes cast by Mettrum shareholders at a special meeting expected to take place in January 2017.

Under applicable TSX rules, the transaction requires the approval of Canopy Growth shareholders by a majority vote, as the number of Canopy Growth common shares to be issued exceeds 25% of the total number of outstanding Canopy Growth common shares, with such approval expected to take place at a special meeting in January 2017. Senior officers and directors of Canopy Growth have also entered into voting support agreements pursuant to which they will vote their common shares in favour of the Arrangement. 

Closing remains subject to approval of the shareholders of both Canopy Growth and Mettrum, court approval, the approval of the TSX, applicable regulatory approvals and the satisfaction of certain other closing conditions customary in transactions of this nature.

Additional details of the Arrangement will be provided to Mettrum and Canopy Growth shareholders in respective information circulars to be mailed in December 2016. It is expected that shareholder meetings and closing of the Arrangement will occur in January 2017.

Board Recommendations

The Board of Directors of both Canopy Growth and Mettrum, have unanimously approved the transaction and recommend that shareholders vote in favour of the transaction. The Board of Directors of Mettrum has acted on the unanimous recommendation of the Special Committee comprised solely of independent directors. Dundee Securities Ltd. provided a fairness opinion to the Board of Directors of Canopy Growth, stating that in its opinion, and based upon and subject to the assumptions, limitations, and qualifications set forth therein, the Exchange Ratio pursuant to the Arrangement is fair, from a financial point of view, to the Canopy Growth shareholders. Cormark Securities Inc. has provided a fairness opinion to the Special Committee of the Board of Directors of Mettrum, stating that in its opinion, and based upon and subject to the assumptions, limitations, and qualifications set forth therein, the Exchange Ratio pursuant to the Arrangement is fair, from a financial point of view, to the Mettrum shareholders.  In addition, Echelon Wealth Partners Inc. provided a fairness opinion to the Special Committee of the Board of Directors of Mettrum, stating that the Arrangement is fair, from a financial point of view, to the Mettrum shareholders, subject to certain assumptions, limitations, and qualifications.

Integrated Quality Assurance Approach

The Company is confident that Mettrum's response to the events that led to the recall will result in operational practices that will advance the quality and standards of the production of cannabis at Mettrum's facilities.

Mettrum will continue to lead site activities with Health Canada as it fulfills its obligations for products affected by the previously announced Type III recall.

Canopy Growth has established a strong multi-site track record of regulatory compliance across diversified production sites, making it uniquely capable of implementing best practices and moving forward to the highest production standards under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR") issued pursuant to the Controlled Drugs and Substances Act (Canada).

Financial and Legal Advisors

Dundee Securities Ltd. is acting as financial advisor to Canopy Growth with LaBarge Weinstein LLP acting as legal advisor to the Company.

Cormark Securities Inc. is acting as financial advisor to Mettrum, Goodmans LLP is acting as legal counsel to Mettrum and Aird & Berlis LLP is acting as legal counsel to the Special Committee of Mettrum.

Conference Call Information

Canopy Growth and Mettrum will host a joint conference call to discuss the transaction on December 1, 2016 at 8:30 a.m. (Eastern Daylight Time). A copy of the presentation can be found on Canopy's Growth's website at www.canopygrowth.com

Calling Information:
Toll Free Dial-In Number: 1-888-231-8191
International Dial-In Number (647) 427-7450
Conference ID: 30771775

Replay Information:
A replay of the call will be accessible by telephone until 11:59 PM ET on January 1, 2017.
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 30771775

A live audio webcast will be available here.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering diverse brands and curated cannabis strain varieties in dried and oil extract forms.  Through its wholly‑owned subsidiaries, Tweed, Tweed Farms, and Bedrocan Canada, Canopy Growth operates three state-of-the-art production facilities with over half a million square feet of indoor and greenhouse production capacity. Canopy Growth has established partnerships with leading sector names in Canada and abroad. For more information visit www.canopygrowth.com.

About Mettrum Health Corp.
Mettrum Health Corp. is a Tier 1 Industry Issuer listed on TSX Venture Exchange. Mettrum Ltd., a wholly-owned subsidiary of Mettrum Health Corp., is a Toronto-based company and a licensed producer of medical cannabis under the ACMPR. Mettrum received its first license from Health Canada on November 1, 2013 and began production of medical cannabis at its first production facility in Bowmanville, Ontario. Mettrum received its second license from Health Canada on December 11, 2014 for its other wholly-owned subsidiary, Agripharm Corp., at the Mettrum Creemore facility in Clearview, Ontario. Mettrum received its third license from Health Canada on December 17, 2015 for Mettrum Ltd. at its new 60,000 square foot production and distribution facility in Bowmanville, Ontario. With the company's three licenses, Mettrum Health Corp. is a leading producer and vendor of medical cannabis under the ACMPR system. In addition, through its wholly-owned subsidiary Mettrum Hempworks, Mettrum also is a licensed producer and distribution of industrial cannabis (hemp) products, including Mettrum's functional food line, Mettrum Originals™, under the Industrial Hemp Regulations (Canada) issued pursuant to the Controlled Drugs and Substances Act (Canada).......

 

29.11.2016 15:38
Bild des Benutzers shanik82
Offline
Kommentare: 8
LDS Patent Filing for Advanced CannaStrips Formulations
29.11.2016 15:25
Bild des Benutzers petra129
Offline
Kommentare: 33

Speculative stock may be best bargain stock of 2016

image: https://www.adviceforinvestors.com/wp-content/uploads/userphoto/210.png

Investor’s Digest columnist Edward Gardiner may be no fan of the new Trudeau Liberal government, but he names one stock that may be the bargain of a generation if the government follows through with its promise to legalize marijuana.

Justin Trudeau’s first year hasn’t been too surprising. Trudeau the Younger has been in power for about a year now, and so far, other than spending a lot of money, he hasn’t caused too much damage.

That’s probably because he hasn’t made good on his more serious campaign promises. But he has laid the groundwork for some of them, so trouble is on the way.

He kept his promise to Statistics Canada about the long-form census questionnaire and now the number crunchers think they should run the country. Personally, I think many Canadians will ‘punish’ Stats Can by falsifying their answers going forward. After all, your answers are confidential, so you can’t be identified. In the meantime, Trudeau has to explain to the bureaucrats that they can’t have everything their own way.

He also kept the ‘internationalists’ happy by announcing that Canada is ‘back’ at the United Nations. Basically, all he did was suck up to a bunch of Third-World dictators and promise them lots of money. With any luck, he won’t ever have to make good on that promise.

On another note, he laid the groundwork for altering our electoral system. Whatever changes are forced on us, they will likely mean more power for party leaders and insiders and less for the ordinary citizen. I’m not sure what impact, if any, this will have on the markets.

Highly speculative play may be best bargain stock for 2016

His most interesting promise is the one to legalize marijuana. This is the one that probably won him the election by buying the votes of many millennials—a group that has had a poor turnout in recent elections, but managed a much better performance this time around.

I am reliably informed (by members of that generation) that many millennials voted for Mr. Trudeau solely because of his promise to legalize marijuana, despite being warned that the Liberal version will likely include a government monopoly and taxes that will make alcohol and tobacco look cheap.

If you want to take advantage of this opportunity, and have a tolerance for speculative stocks, you might consider Canopy Growth Corp. (TSX—CGC). It has no earnings yet, so I won’t buy it myself, but as a highly speculative stock it may be all right. And in 20 or 30 years, it, or others like it, should be highly profitable. The millennials are going to need those profits to pay for Trudeau’s largesse.

Read more at http://www.stockhouse.com/companies/bullboard/v.cgc/capital-gold-corpora...

 

....dass ich diese Aktie "verschenkt" habe ärgert mich schon....sehr! Fool

 

Seiten